You are here
Trial results on same-day discharge for elective implantable cardioverter-defibrillator procedures may reassure centers, but whether the approach lowers cost is anyone’s guess.
Behind-the-scenes contributions from nursing are helping make TAVR a success story. Recognition of their value also is raising nursing’s profile in the cardiovascular community.
CIEDs with remote monitoring capabilities can provide a wealth of information, yet some physicians and hospitals aren’t making the most of this resource.
Health systems and practices are encountering new pressures as the number of adults with CHD expands.
A disconnect between best care and what Medicare is willing to reimburse for it has put some electrophysiologists and their hospitals in a bind.
Will noninferior results be good enough to win over cardiologists and payers?
One morning last year, a patient checked into a hospital in Canada as the first TAVR case of the day.
Endovascular treatment has emerged as the best thing since intravenous tissue plasminogen activator (IV t-PA) for acute ischemic stroke after five recent studies showed positive outcomes. Stent retrievers starred in the trials, with imaging playing a critical supporting role. But in clinical practice, which neuroimaging method best identifies likely beneficiaries is up for debate.
The stars appear to be aligned for drugs that reverse the effect of novel oral anticoagulants (NOACs). Regulators in the U.S. have moved them forward, anxious to provide emergency physicians an antidote in cases of life-threatening bleeding. But the ultimate beneficiaries may be patients who need but don’t take anticoagulants because of bleeding fears.
PCI-related bleeding events potentially carry a host of unwanted consequences.